AM.I. has received grants and advisory fees from Takeda and Novartis. G.A. has been Principal Investigator of Research Studies for Novartis; has received research grants from Novartis and Takeda; has received speaker fees from Novartis; and has received consulting fees from Novartis and Pfizer, Inc. as board member. M.B. has been Principal Investigator of Research Studies for Novartis; has been Investigator of Research Studies for Novartis, HRA Pharma and ViroPharma; and has received consulting fees from Novartis as board member. A.F. declares that he has received a speaker honorarium from Shire Italy S.p.A. C.G. has been Principal Investigator of Research Studies for Novo Nordisk and Lilly USA, LLC; has received research grants from Novo Nordisk and Lilly USA, LLC; has been an occasional consultant for Novartis, Pfizer, Inc., Ipsen and Shire; and has received speaker fees from Novo Nordisk, Lilly USA, LLC and Novartis. R.G. has been occasional consultant for Shire. R.P. has been Principal Investigator of Research Studies for Novartis, HRA Pharma, Ipsen, Shire, Corcept Therapeutics, Cortendo AB; Co-investigator of Research Studies for Pfizer; received research grants from Novartis, Pfizer, Ipsen, HRA Pharma, Shire, IBSA; has been an occasional consultant for Novartis, Ipsen, Pfizer, Shire, HRA Pharma, Cortendo AB, Ferring and Italfarmaco; and has received fees and honoraria for presentations from Novartis, Shire. C.S. has been occasional consultant for Shire and Ipsen. C.S. has been Principal Investigator of Research Studies for Novartis, Otsuka and Pfizer, Inc.; has been Co-investigator of Research Studies for Novartis and Lilly USA, LLC; has received research grants from Novartis, Lilly USA, LLC, Otsuka and Pfizer, Inc.; has been an occasional consultant for Novartis and Otsuka; and has received speaker fees for presentations from Otsuka and Lilly USA, LLC. A.L. has received grants and advisory fees from Takeda and Novartis. V.H., R.P., M.A.V and E.S. have no conflicts of interest.